Salem, Massachusetts (PRWEB) October 03, 2013
Commonwealth Laboratories, Inc. and Cedars-Sinai Medical Center announce the signing of an exclusive license agreement for three patents owned by Cedars-Sinai that cover technology developed by Mark Pimentel, M.D., FRCPC, Director of Cedars-Sinai’s Gastrointestinal Motility Program and Laboratory, and Henry C. Lin, M.D. These patents describe the use of hydrogen and methane breath testing in the diagnosis of Irritable Bowel Syndrome and other disorders caused by Small Intestinal Bacterial Overgrowth.
Small Intestinal Bacterial Overgrowth (SIBO) is a condition in which abnormally large amounts of bacteria—100,000 bacteria per ml of fluid or more—are present in the small intestine. Prominent gastroenterologists, including Dr. Pimentel, have identified SIBO as a leading cause of Irritable Bowel Syndrome (IBS).
IBS is one of the most prevalent chronic medical conditions in the world today. It is estimated that 60 million Americans, and between ten (10) and twenty (20) percent of the world population, suffer from the disorder. Hydrogen and methane breath testing is recognized by the American College of Gastroenterology as a non-invasive, patient-friendly method of diagnosing SIBO. Bacterial overgrowth can be identified quickly and efficiently by measuring for levels of hydrogen and methane in exhaled air.
Cedars-Sinai is internationally renowned for its diagnostic and treatment capabilities and its broad spectrum of programs and services, as well as advances in biomedical research and innovative medical education programs. For more than 20 years, Los Angeles-area residents have named Cedars-Sinai the "Most Preferred Hospital for All Health Needs" in National Research Corporation’s annual Healthcare Market Guide survey. Cedars-Sinai Medical Group and Cedars-Sinai Health Associates both ranked among the top 10 physician groups in Southern California by Integrated Health Care Associates (IHA), a California leadership group of health plans, physician groups, and health systems.
About Commonwealth Laboratories, Inc.
Headquartered in Salem, Massachusetts; Commonwealth Laboratories is a state and federally licensed, FDA-registered independent diagnostic laboratory offering specialized, clinical hydrogen and methane breath analysis services to aid in the diagnosis of SIBO and other malnutrition disorders.
If you would like more information about these services, please call Commonwealth Laboratories at (800) 292-9019, e-mail customerservice(at)commlabsinc(dot)com, or visit the website at http://www.hydrogenbreathtesting.com.